Impax Laboratories (IPXL) : 2 days before expiry, shorts in Impax Laboratories (IPXL) have reduced from 5,574,297 on Jul 29, 2016, to 3,238,440 on August 15, 2016. On an average, 1,677,726 shares are traded on the exchange. The outstanding bearish positions are equal to 4.7% of the float. Short sellers have covered -2,335,857 shares, a reduction of -41.9%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Impax Laboratories (NASDAQ:IPXL): The stock opened at $23.99 on Wednesday but the bulls could not build on the opening and the stock topped out at $25.25 for the day. The stock traded down to $23.65 during the day, due to lack of any buying support eventually closed down at $23.79 with a loss of -0.34% for the day. The stock had closed at $23.87 on the previous day. The total traded volume was 2,079,521 shares.
In a related news, Benet Leslie Z, director of Impax Laboratories Inc, unloaded 10,092 shares at an average price of $22.81 on August 15, 2016. The total amount of the transaction was worth $230,199, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Companys generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.